A poster analysis of the phase 3 ADVANCE OUTCOMES trial, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that oral ralinepag reduced clinical worsening across different baseline risk profiles in patients with pulmonary arterial hypertension...
Lung Diseases
Learn about the symptoms, causes, management and available treatments of rare lung disorders. Perspectives on the latest clinically relevant research, guideline updates, and new drug approvals.
PHINDER Analysis Highlights the Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease
Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with interstitial lung disease (ILD).
Highlights from The Liver Meeting 2026 | The CheckRare Brief
In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics.
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF).
More
Phase 3 OASIS Study Shows Promise of Oral Olorofim for Invasive Aspergillosis
Johan Maertens, MD, PhD, Professor of Hematology at University Hospitals Leuven (UZ Leuven) in Belgium and Principal Investigator of the OASIS study, discusses positive phase 3 trial results...
3D Printed Treatment Options | The CheckRare Brief
In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options. New...
FDA Grants Accelerated Approval to Voceryq for Recurrent Respiratory Papillomatosis
The US Food and Drug Administration (FDA) has granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce...
New Formulation of Berotralstat Approved for Adults and Adolescents With Hereditary Angioedema
The US Food and Drug Administration (FDA) has approved the oral pellet formulation of once-daily Orladeyo (berotralstat) for prophylactic therapy in patients ages 12 years and older with hereditary...
Ultragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare Brief
On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays....
Ultragenyx Sells PRV for $210M | The CheckRare Brief Ep 11
In this episode, we discuss Ultragenyx’s Priority Review Voucher that sold for $210 million, the efficacy of newborn screening on MLD, and ethical considerations needed to design and conduct...
Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
Jorge Nieva, MD, Associate Professor at the Keck School of Medicine, discusses new analyses from the TRUST studies evaluating taletrectinib in patients with ROS1-positive non-small cell lung cancer...
Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10
On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It's the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. ...
FDA CDER’s Accelerating Rare Disease Cures Program
Paz Vellanki, MD, PhD, Vice President of Clinical Development at Precision for Medicine, discusses the FDA CDER’s Accelerating Rare Disease Cures (ARC) Program. The ARC Program was launched...
Safety and Efficacy of Ralinepag in Patients With Pulmonary Arterial Hypertension
A study published in The Lancet evaluated the safety and efficacy of ralinepag in patients with pulmonary arterial hypertension (PAH). PAH is a rare condition affecting the heart and lungs,...
New Rare Disease Center of Excellence and FDA Advances in Rare Disease | The CheckRare Brief Ep 9
This week on The CheckRare Brief, we are joined by Eugene Lee, CMI Media Group’s Group President, Specialty Communications, for an industry perspective on some of the biggest developments in rare...
Phase 3 Results of Inhaled Treprostinil in Patients With Idiopathic Pulmonary Fibrosis
A study published in The New England Journal of Medicine examined results from the phase 3 TETON-1 clinical trial of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF). IPF is a rare,...
FDA Approves New Therapies for MPS IIIA and SMA | The CheckRare Brief Ep 8
This week we discuss the FDA's approval of Isembyld for SMA, the approval of a gene therapy for MPS IIIA, and the FDA's Center for Devices and Radiological Health new Rare Disease Impact...
Pulmonary Arterial Hypertension and Risk of Mental Health Comorbidities
A study published in Pulmonary Circulation evaluated the association between pulmonary arterial hypertension (PAH) diagnosis and risk of newly diagnosed mental health conditions. PAH is a rare...
First-Line Therapy Approved for Rare Lung Cancer | The CheckRare Brief Ep 7
This week, three developments highlight the rapidly changing rare disease treatment landscape: a Phase 3 setback in Angelman syndrome, continued competition in hereditary angioedema, and an...
New Huntington’s Disease Gene Therapy Application | The CheckRare Brief Ep 6
In this episode of The CheckRare Brief, we discuss two recent FDA approvals for rare diseases, including Zanvastro for Alexander disease and Besremi for essential thrombocythemia (ET). We...
Data on Maribavir in Post-Transplant Cytomegalovirus
Neil Inhaber, MD, FRCPC, Therapeutic Area Head of Global Medical, Rare Disease at Takeda, discusses data on maribavir in post-transplant cytomegalovirus (CMV) presented at the American Transplant...
New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | The CheckRare Brief Ep 5
In this episode of The CheckRare Brief, we discuss four recent FDA approvals, including LISRAYA for dermatomyositis and Imaavy for warm autoimmune hemolytic anemia (wAIHA), Mimrylo for...
Getting a Rare Disease Drug Approved Is Only Half the Battle | The CheckRare Brief Ep 4
FDA approval is a major milestone, but for patients with rare diseases, it is only the beginning. In this episode of The CheckRare Brief, we look at two new rare disease approvals, ongoing...
FDA Approves New Narcolepsy Treatment | The CheckRare Brief
On this week’s episode of The CheckRare Brief, we discuss FDA's approval of Orzeyful (oveporexton) to treat patients with narcolepsy type 1, CAMP4’s first-in-human clinical trial for patients...
Recent Videos
Analysis Finds Ralinepag Reduces Clinical Worsening Across PAH Risk Profiles
Interim PHINDER Analyses in Interstitial Lung Disease
The Need for Earlier Pulmonary Hypertension Screening in Interstitial Lung Disease
TETON-2 Findings in Treatment of Idiopathic Pulmonary Fibrosis #podcast #raredisease





Ralinepag for Pulmonary Arterial Hypertension
CheckRare 5 hours ago